Phase 1, Randomized, Double-Blind, Vehicle-Controlled Study of Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Subjects With Female Pattern Hair Loss
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs HSC-660 (Primary)
- Indications Alopecia
- Focus Adverse reactions
- Sponsors Histogen
- 20 Feb 2019 Planned End Date changed from 15 Mar 2019 to 21 Jan 2021.
- 20 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 28 Jan 2019 According to a Histogen media release, data are anticipated in 2019.